Twitter Facebook LinkedIn YouTube

Alpha Cognition’s lead drug is ALPHA-1062, a patented new chemical entity developed for the treatment of mild to moderate Alzheimer’s Dementia

Video Platform Video Management Video Solutions Video Player

The drug, with patent protection extending to 2040, is designed to be a best-in-class medicine that minimizes major treatment-limiting side effects and improves long term outcomes for patients.

Additional Information:

Company: Alpha Cognition Inc.
Website: http://www.AlphaCognition.com
Stock Symbol: TSXV: ACOG
Date Published: Mar 31, 2021
Transcript: Available

Video Transcript:

I’m Ashton Addison for Investmentpitch Media

Alpha Cognition Inc., a late-stage biopharmaceutical company focused on neurology, is one of the latest new listings on the TSX Venture Exchange, trading under the symbol “ACOG”, following its qualifying transaction with Capital Pool Company Crystal Bridge Enterprises.

Alpha Cognition’s lead drug is ALPHA-1062, a patented new chemical entity developed for the treatment of mild to moderate Alzheimer’s Dementia.

ALPHA-1062 is following the de-risked 505(b)(2) new drug application pathway with a high probability of success and is entering a pivotal study for which near term FDA approval is expected.

The drug, with patent protection extending to 2040, is designed to be a best-in-class medicine that minimizes major treatment-limiting side effects and improves long term outcomes for patients.

Alzheimer’s Disease, a progressive neurodegenerative disease for which there is no present cure, causes memory loss, behavioral changes, and loss of physical function.

It impacts an estimated 6 million people in the U.S. with one new person diagnosed every 65 seconds.

Treating Alzheimer’s Disease is a large and growing market with a high and presently unmet medical need.

In 2019, there were approximately 12 million prescriptions dispensed for the current therapy.

Current therapies come with many side effects which include nausea, vomiting and diarrhea that lead to poor tolerability and high rates of discontinuation by patients.

ALPHA-1062’s formulation enables the drug to decrease these harsh side effects while increasing its bioavailability into the brain, thereby potentially creating a best-in-class profile.

In addition to ALPHA-1062, the company has a robust and growing pipeline that includes ALPHA-1062 + Memantine for the treatment of moderate-to-severe Alzheimer’s dementia, ALPHA-1062 intranasal delivery for traumatic brain injury and ALPHA-0602 for ALS, which has been granted Orphan Drug Designation by US FDA.

The company raised gross proceeds of approximately $5.4 million ($5,376,198) from the placement of approximately 3.4 million (3,360,124) units priced at $1.60 per unit.

Each unit consisted of one share and one-half a warrant, with the full warrant exercisable at $2.10 for 24 months.

The brokered private placement was led by Raymond James.

The shares are trading at $1.25.

For more information, please visit the company’s website www.AlphaCognition.com, contact Kenneth Cawkell, CEO, at 604-837-7990 or email KCawkell@AlphaCognition.com.

Investor Relations is handled by Glen Akselrod of Bristol Investor Relations, who can be reached at 905-326-1888 Ext 1 or by email at glen@bristolIR.com.

I’m Ashton Addison for Investmentpitch Media